Another example of a biotech once left for dead an
Post# of 72447
(Total Views: 287)
Posted On: 03/06/2019 9:26:18 AM
Another example of a biotech once left for dead and now successful. You don't need to read this article or care about their drug (not relevant to IPIX) to understand the chart.
Article
https://endpts.com/focused-on-its-2nd-commerc...givosiran/
Chart
http://bigcharts.marketwatch.com/quickchart/q...mp;time=20
By the way, they have a 9.3 Billion market cap, are not profitable, are projected to lose money again this year (lots of money), and just had a mixed-result clinical trial -- results were good but bad side effects.
They have one approved drug, which their 2nd drug might replace. It is for a rare disease.
So, a 9.3 Billion market cap for a company that is unlikely to affect as many patients as Brilacidin-OM would reach.
IPIX market cap is just under 26 Million.
Efficient markets, what a laugh.
Article
https://endpts.com/focused-on-its-2nd-commerc...givosiran/
Chart
http://bigcharts.marketwatch.com/quickchart/q...mp;time=20
By the way, they have a 9.3 Billion market cap, are not profitable, are projected to lose money again this year (lots of money), and just had a mixed-result clinical trial -- results were good but bad side effects.
They have one approved drug, which their 2nd drug might replace. It is for a rare disease.
So, a 9.3 Billion market cap for a company that is unlikely to affect as many patients as Brilacidin-OM would reach.
IPIX market cap is just under 26 Million.
Efficient markets, what a laugh.
(5)
(0)